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Abstract
Background: Insulin is a vital peptide hormone that is a central regulator of glucose homeostasis, and impairments in
insulin signaling cause diabetes mellitus. In principle, it should be possible to enhance the activity of insulin by inhibiting its
catabolism, which is mediated primarily by insulin-degrading enzyme (IDE), a structurally and evolutionarily distinctive zinc-
metalloprotease. Despite interest in pharmacological inhibition of IDE as an attractive anti-diabetic approach dating to the
1950s, potent and selective inhibitors of IDE have not yet emerged.
Methodology/Principal Findings: We used a rational design approach based on analysis of combinatorial peptide mixtures
and focused compound libraries to develop novel peptide hydroxamic acid inhibitors of IDE. The resulting compounds are
,10
6 times more potent than existing inhibitors, non-toxic, and surprisingly selective for IDE vis-a `-vis conventional zinc-
metalloproteases. Crystallographic analysis of an IDE-inhibitor complex reveals a novel mode of inhibition based on
stabilization of IDE’s ‘‘closed,’’ inactive conformation. We show further that pharmacological inhibition of IDE potentiates
insulin signaling by a mechanism involving reduced catabolism of internalized insulin.
Conclusions/Significance: The inhibitors we describe are the first to potently and selectively inhibit IDE or indeed any
member of this atypical zinc-metalloprotease superfamily. The distinctive structure of IDE’s active site, and the mode of
action of our inhibitors, suggests that it may be possible to develop inhibitors that cross-react minimally with conventional
zinc-metalloproteases. Significantly, our results reveal that insulin signaling is normally regulated by IDE activity not only
extracellularly but also within cells, supporting the longstanding view that IDE inhibitors could hold therapeutic value for
the treatment of diabetes.
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Introduction
Insulin is a tightly regulated peptide hormone that is centrally
invovled in multiple vital physiological processes, ranging from
energy and glucose homeostasis to memory and cognition [1,2,3].
The tertiary structure of insulin is unique among peptide
hormones, being comprised of 2 peptide chains and containing 1
intra- and 2 interchain disulfide bonds, and the relative rigidity and
bulk of insulin render it a poor substrate for most proteases [4].
The proteolytic degradation and inactivation of insulin is believed
to be mediated primarily by insulin-degrading enzyme (IDE), a
ubiquitously expressed, soluble, secreted zinc-metalloprotease [5,6].
IDE belongs to a small superfamily of zinc-metalloproteases (clan
ME, family M16) that evolved independently of conventional zinc-
metalloproteases [7]. Members of this superfamily are commonly
referred to as ‘‘inverzincins,’’ because they feature a zinc-binding
motif (HxxEH) that is inverted with respect to that within
conventional zinc-metalloproteases (HExxH) [8].
Like insulin, IDE is structurally distinctive, consisting of two
bowl-shaped halves connected by a flexible linker that can switch
between ‘‘open’’ and ‘‘closed’’ states [9]. In its closed state, IDE
completely encapsulates its substrates within an unusually large
internal cavity [9] that appears remarkably well-adapted to
accommodate insulin [10]. IDE degrades several other interme-
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and the amyloid b-protein (Ab) [11]; however, unlike insulin, most
other IDE substrates are known to be hydrolyzed by multiple
proteases.
Diabetes melittus is a life-threatening and highly prevalent
group of endocrinological disorders that, fundamentally, are
characterized by impaired insulin signaling. Correspondingly, it
is the common goal of most anti-diabetic therapies to enhance
insulin signaling, either by direct injection of insulin, by
stimulating the production or secretion of endogenous insulin, or
by activating downstream targets of the insulin receptor (IR)
signaling cascade [12]. In principle, it should be possible to
enhance insulin signaling by inhibiting IDE-mediated insulin
catabolism [13]. Pharmacological inhibitors of IDE in fact
attracted considerable attention in the decades following the
discovery of IDE in 1949 [14]. Quite significantly, a purified
inhibitor of IDE (of undetermined identity) was found to potentiate
the hypoglycemic action of insulin in vivo as early as 1955 [15].
Despite more than 60 years of research on IDE and its
involvement in insulin catabolism, the development of small-
molecule inhibitors of IDE has proved to be a surprisingly
elusive goal [16]. We describe herein the design, synthesis,
enzymologic characterization, and enzyme-bound crystal struc-
ture of the first potent and selective inhibitors of IDE. In
addition, we show that inhibition of IDE can potentiate insulin
signaling within cells, by reducing the catabolism of internalized
insulin. These novel IDE inhibitors represent important new
pharmacological tools for the experimental manipulation of IDE
and, by extension, insulin signaling. Furthermore, our results
lend new support to the old idea that pharmacological inhibition
of IDE may represent an attractive approach to the treatment of
diabetes mellitus.
Results
Compound screening fails to identify effective IDE
inhibitors
The few IDE inhibitors currently in use are generally non-
selective and/or highly toxic, and all suffer from extremely low
potency, requiring mM concentrations to achieve complete
inhibition (Table S1). To develop improved inhibitors of IDE,
we initially conducted high-throughput screening on ,115,000
compounds, using a previously developed Ab degradation assay
[17]. Although several inhibitors were discovered, most of these
were either toxic, thiol-alkylating compounds [18] (Fig. S1A) or
were compounds acting through other mechanisms that proved
difficult to improve despite extensive medicinal chemistry
optimization efforts (Fig. S1B). Among the remaining inhibitors,
just a single compound, known as nullscript [19] (Fig. S1C),
exhibited submicromolar IC50 values.
Nullscript is predicted to target the active site of IDE because it
contains the potent hydroxamic acid zinc-binding moiety, but it
proved ineffective in cell-based assays (not shown). Consequently,
we tested a range of peptidic and nonpeptidic hydroxamate
inhibitors of conventional metalloproteases for possible effects on
IDE. Surprisingly, IDE was unaffected by any of the nonpeptidic
hydroxamates tested, some of which were potent inhibitors of a
broad range of zinc-metalloproteases, and was only weakly
inhibited by peptidic versions (Table S2). This result provides a
striking confirmation that IDE’s active site—though obviously
optimized to accommodate peptides—is indeed substantially
different from the active site within canonical zinc-metallopro-
teases, raising the possibility that highly selective zinc-binding
inhibitors might be developed.
Potent IDE inhibitors developed using a classic design
strategy
These initial results prompted us to revisit the classic design
strategy originally used to develop zinc-metalloprotease inhib-
itors [20]. The general approach is to attach a zinc-binding
moiety to short peptides that correspond to the cleavage-site
specificity of the protease of interest [21]. Because IDE lacks a
clear cleavage-site specificity deducible from known substrates,
we determined this de novo through proteomic analysis of the
cleavage sites within combinatorial mixtures of short peptides
(see Methods) [22]. This analysis revealed that IDE has a strong
preference for Tyr<Arg . Phe at the P1’ position and for Arg at
the P2’ position, while showing relatively little specificity at the
remaining sites (Fig. 1A).
Based on this analysis and considerations of synthetic
tractability, we initially generated inhibitors based on the
peptide Phe-Arg-Trp-Glu. A hydroxamic acid moiety was
attached to the N-terminus, positioned appropriately by the
inclusion of an a carbonyl moiety [21]. We generated pure
diastereomers containing either all L-amino acids or a D-amino
acid at the P1’ position, yielding Ki values of 0.11 (Fig. 1B) and
4.1 mM, respectively. While these compounds are far more
potent than previously described IDE inhibitors, their potency is
poorer than is typically achieved with peptide hydroxamates,
and they proved non selectivew h e nt e s t e da g a i n s to t h e r
metalloproteases (not shown). We postulated that these defi-
ciencies were related to the incorporation of Phe at the P1’
position, which was not as strongly or uniquely preferred as Tyr
or Arg (Fig. 1A). To optimize the P1’ position, we generated a
focused library of peptide hydroxamates based on the sequence
Xaa-Arg-Tyr, where Xaa represented a variety of natural and
unnatural amino acids (Fig. 2A). These peptides were generated
by solid-phase peptide synthesis in the ‘‘retro-inverso’’ config-
uration, wherein the peptide backbone is reversed with respect
to conventional peptides (see Fig. S2). The retro-inverso
configuration required the use of all D-amino acids, and the
need to incorporate an additional a carbon between the
hydroxamic acid and the peptide sequence required the use of
b-amino acids at the P1’ position. A ,100-fold gain in potency
was realized when Phe was substituted with 2-naphthylalanine
(2-Nap; Fig. 2B). We then generated a conventional peptide
hydroxamate incorporating 2-Nap at the P1’ position, yielding
an inhibitor, Ii1 (IDE inhibitor 1; Fig. 1C), with a Ki value of
,1.7 nM, or .10
5 more potent than IDE inhibitors currently
in use (c.f.,T a b l eS 1 ) .
Novel enzymological properties and unanticipated
selectivity of Ii1
Enzymatic analysis of inhibitor Ii1 (Fig. 3) revealed several
unexpected properties. First, the Ki values computed for Ii1 were
found to be substrate dependent, with shorter substrates yielding
lower values, and longer substrates—such as insulin and Ab—
yielding values consistently ,10-fold higher (Fig. 3A). It is notable
that a similar pattern of substrate dependence has consistently
been observed for pharmacological activators of IDE [23] (see
Discussion). In agreement with this result, Ii1 exhibited a purely
competitive mode of inhibition of the hydrolysis of insulin (Fig. 3B)
and Ab (Fig. S3). Second, the Hill slopes for inhibition of all
substrates tested were ,1, suggesting some degree of negative
cooperativity. Finally, and rather unexpectedly for this type of
inhibitor, Ii1 proved to be remarkably selective for IDE vis-a `-vis a
wide range of conventional zinc-metalloproteases and representa-
tive members of other protease classes (Fig. 3C).
Inhibitors of IDE
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of inhibition
To elucidate the mechanistic basis for these intriguing
properties, we solved the co-crystal structure of Ii1 complexed to
catalytically inactive, cysteine-free human IDE at 2.6-A ˚ resolution
(Fig. 4; Fig. S4; Table S3). The mode of binding of Ii1 is
remarkable in several key respects, which have attendant
implications for IDE’s mechanism of catalysis and for future drug
design. First, the IDE-inhibitor interaction is restricted to the
catalytic zinc and subsites S1’ and S2’ (Fig. 4A). The P3’ and P4’
residues of Ii1 face the center of the catalytic chamber of IDE and
do not contact IDE directly; consequently, only the main chain of
these two residues could be modeled (Fig. 4B). This is consistent
with IDE’s strong cleavage-site preferences at P1’ and P2’ and
weak preferences at P3’ and P4’ (Fig. 1A).
Second, the active site of IDE is configured such that the P1’ and
P2’ residues of Ii1 both point away from IDE’s internal chamber
(Fig. 4A,B), thereby inducing a partial turn within the amide
backbone of Ii1. This partial turn, which is also present within
several full-length IDE substrates [9], appears to be a structural
prerequisite permitting extended peptides to fit within IDE’s
internal chamber. This configuration would appear to disfavor
hydrolysis of substrates that extend from the inside to the outside
of the protease, a feature that likely accounts for IDE’s inability to
process larger protein substrates and its lack of exopeptidase
activity.
Finally, and quite significantly, Ii1’s hydroxamate moiety, amide
backbone, and P2’ residue all make substantial interactions not
only with residues in the N-terminal portions of IDE involved in
zinc-binding and catalysis, but also with multiple residues within
distal C-terminal portions of the protease (Fig. 4B; Fig. S4). This
finding highlights the fact that IDE’s active site is not completely
formed unless and until the N- and C-terminal portions of the
protease are juxtaposed, which occurs only in the closed
conformation and only during a portion of IDE’s catalytic cycle
[9,18]. Consequently, Ii1 appears to inhibit IDE not only by
active-site blockade but also by the novel mechanism of locking
IDE in the closed, inactive conformation. Together, these atypical
attributes of IDE’s active site and its catalytic mechanism may
Figure 2. IDE inhibition by a focused library of retro-inverso
peptide hydroxamates containing modifications at the P1’
position. A, Structure of compound library. Note that compounds
were generated in the retro-inverso configuration (see Fig. S2). B,
Relative Ki values of inhibitors containing different R groups (see A).
doi:10.1371/journal.pone.0010504.g002
Figure 1. Cleavage-site specificity of IDE and first-generation inhibitors derived therefrom. A, Heat map showing amino acids favored
(red) or disfavored (green) by IDE at different positions relative to the cleavage site, as determined from proteomic analysis of peptide mixtures. B,
Conventional peptide hydroxamate synthesized on the basis of the analysis in (A). C, Structure of inhibitor Ii1, incorporating optimized P1’ moiety
deduced from analysis of a focused library of retro-inverso peptide hydroxamates (see Figure 2).
doi:10.1371/journal.pone.0010504.g001
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PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10504account for the long-standing elusiveness of small-molecule IDE
inhibitors, while at the same time auguring well for the eventual
development of highly selective compounds (see Discussion).
Unexpected potency of derivatized IDE inhibitors
Because retro-inverso peptide hydroxamates could be generated
with facility by solid-phase peptide synthesis, we explored the
development of affinity labeled versions containing benzoylphe-
nylalanine at either the P2’o rP 3’ position together with a
fluorescent EDANS label, and in some cases, a biotin group
attached via a polyethylene glycol linker. The biotinylated versions
avidly labeled recombinant IDE, but showed rather broad cross-
reactivity in cell lysates under the conditions tested (not shown),
probably due in part to their very large size (,1600 Da).
Surprisingly, however, the addition of these extraneous function-
alities resulted in considerable increases in potency, with Ki values
in the range of 0.3 to 4 nM (Table S4), an effect that we speculate
may relate to a reduced off rate due to entrapment within IDE’s
internal chamber. Importantly, this effort resulted in the
generation of 4-amino acid retro-inverso compounds that, relative
to Ii1, were not only comparable in size and potency but also
contained divergent residues at all positions but P1’( e.g., ML3-XF;
Table S4). Moreover, the inverted peptide backbone in these
compounds is predicted to render them more resistant to
degradation than conventional peptidic inhibitors, and they
proved useful in downstream cellular assays.
Effects on catabolism of extracellular and prebound
insulin
To assess the utility of these novel IDE inhibitors as chemical
probes, we examined their effects on a range of endpoints
relevant to insulin catabolism and signaling in cultured cells. In
Figure 3. In vitro enzymatic analysis of IDE inhibition by Ii1. A, Representative dose-response curves for a variety of IDE substrates and Ki
values and Hill slopes computed from 4 to 6 replications per substrate. Note that [S]/KM was kept constant for dose-response studies, permitting
visual comparison of relative Ki values. B, Lineweaver-Burk plot of IDE-mediated insulin degradation in the absence or presence of Ii1 (30 nM) and
kinetic parameters calculated from 4 independent experiments. These data were obtained using recombinant human insulin and
125I-insulin at a fixed
ratio (1000:1), as described [48]. Note that the mode of inhibition is purely competitive, and was also observed using Ab (Fig. S3). C, Dose-response
curves showing the selectivity of Ii1 for IDE as compared to several other zinc-metalloproteases—neprilysin (NEP), endothelin-converting enzyme-1
(ECE1), angiotensin-converting enzyme-1 (ACE1) and matrix-metalloprotease-1 (MMP1)—and representative members of other protease classes,
including cysteine (cathepsin B), aspartate (cathepsin D), serine (trypsin and plasmin) and threonine (20S proteasome). Data are mean of 2 to 3
experiments per condition.
doi:10.1371/journal.pone.0010504.g003
Inhibitors of IDE
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10504CHO cells overexpressing the human insulin receptor (IR)
(CHO-IR cells) (Fig. 5A) and HeLa cells (Fig. S5A), Ii1 inhibited
the degradation of extracellular insulin dose-dependently, with
IC50s comparable to that obtained in vitro (c.f.,F i g .3 A ) .N o t a b l y ,
at mM concentrations, insulin catabolism was inhibited essen-
tially completely (Fig. 5B; Fig. S5B), consistent with other
evidence implicating IDE as the major extracellular insulin
protease [5]. No toxicity was observed for Ii1 or ML3-XF up to
100 mM( F i g .S 6 ) .
Because IDE is in part a secreted protease [24], its role in
degrading extracellular insulin is not surprising. By contrast, the
extent to which IDE participates in the degradation of
internalized insulin remains controversial. The prevailing dogma
suggests that, following binding to the IR, insulin is rapidly
endocytosed and then degraded in acidic compartments of the
endolysosomal system [25]. Consistent with this view, the aspartyl
protease cathepsin D has been implicated in the degradation of
internalized insulin [26]. On the other hand, IDE has been
Figure 4. Structure of human IDE complexed to inhibitor Ii1. A, Overall structure of Ii1-bound IDE. Ribbon diagram of monomeric IDE colored
as green, blue, yellow and red for domains 1, 2, 3 and 4, respectively (left). The connecting loop between IDE-N and IDE-C is shown in cyan.2 Fo–Fc
simulated annealing omit map contoured at 1 s is shown in blue around Ii1 (right). In this view, the C-terminal domains of IDE (yellow, red) have been
omitted to highlight the interactions of Ii1 with the catalytic zinc atom in the N-terminal domain of IDE. B, Stereodiagram showing the detailed
interactions of Ii1 with residues and zinc ion in the catalytic site of IDE. Protein residues involved in catalysis and in contact with Ii1, as well as the
inhibitor are drawn in stick representation. Residues from the C-terminal half of IDE are underlined and highlighted in yellow. Ii1 in stick representation
is colored the same as in (A). Carbon nitrogen and oxygen atoms of Ii1 are colored orange and those of IDE grey; nitrogen and oxygen atoms are
colored blue and red, respectively; zinc and water are represented by spheres colored magenta and red, respectively. Hydrogen bonds are shown as
dashed lines. Figures generated using Pymol [50].
doi:10.1371/journal.pone.0010504.g004
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insulin at neutral pH [27]. The development of Ii1—which
potently inhibits IDE, but not cathepsin D (Fig. 2C)—enabled us
for the first time to address cleanly this longstanding controversy.
To that end, we conducted live-cell imaging of CHO-IR cells
loaded with fluorescent insulin labeled exclusively at the N-
terminus of the B chain with fluorescein isothiocyanate (FITC-
ins), a modification that has been shown not to interfere with
binding to the IR [28]. FITC-ins-loaded cells were washed then
monitored for changes in fluorescence in the presence of Ii1 or
vehicle (Fig. 5C). In vehicle-treated cells, intracellular fluores-
cence decreased (Fig. 5D) and extracellular fluorescence
increased (Fig. 5E) monotonically with time. By contrast, both
intra- and extracellular fluorescence remained essentially constant
in the presence of Ii1 (Figs. 5D,E). Consistent with previous
studies of insulin catabolism[29], the fluorescent species secreted
by vehicle-treated cells were confirmed to be proteolytic
fragments of FITC-ins (Fig. S7). These results strongly suggest
that the catabolism of internalized insulin is primarily, if not
exclusively, carried out by IDE.
Unanticipated effects of IDE inhibitors on insulin
signaling
Given the historic interest in IDE inhibition as a potential
antidiabetic treatment, we assessed the effects of our novel
inhibitors on insulin signaling. To simplify interpretation, we
focused on the most upstream event in the insulin signaling
cascade: IR autophosphorylation. To that end, CHO-IR cells
were loaded with insulin at 4uC and washed extensively (in the
absence of inhibitors), then warmed to 37uC for 5 min in the
presence of IDE inhibitors (10 mM) or vehicle alone. The degree of
insulin-stimulated (but not basal) IR autophosphorylation was
consistently potentiated in the presence of Ii1 or the retro-inverso
IDE inhibitor, ML3-XF (Fig. 5F; Table S4). Though surprisingly
brief, the time-scale of this effect is consistent with classic studies of
insulin degradation showing that the prebound pool of insulin is
degraded very rapidly [29]. To verify this in our experimental
system, we directly quantified the degree of degradation of
125I-
insulin prebound to CHO-IR cells. In good agreement with
previous studies [29], prebound
125I-insulin decreased ,30%
within 5 min at 37uC in vehicle-treated cells, an effect that was
inhibited completely by Ii1 and ML3-XF (Fig. 5G).
Taken together, these results suggest that IDE normally
regulates insulin signaling by virtue of its ability to rapidly degrade
internalized pools of insulin; correspondingly, insulin signaling can
be potentiated significantly by inhibiting IDE proteolytic activity.
In addition to illustrating the utility of our novel compounds as
experimental probes, these findings lend fresh support to the long-
standing prediction that IDE inhibitors could hold therapeutic
potential as primary or adjunct treatments for diabetes.
Discussion
Here we describe the rational design, synthesis, enzymologic
characterization, and co-crystallographic analysis of potent and
selective peptide hydroxamate inhibitors of IDE. In addition, we
use these compounds to show that IDE regulates fundamental
aspects of insulin catabolism and signaling in a manner that
implies that IDE inhibitors could have anti-diabetic properties.
Although the inhibitors described in this study are unlikely to have
immediate value as therapeutic agents due to their peptidic nature,
their development and the chemical biology they make possible
are significant in several important respects.
Figure 5. Effects of IDE inhibitors on insulin catabolism and signaling in cells. A, Dose-response curve of Ii1-mediated inhibition of insulin
degradation by CHO-IR cells. Note that the potency of Ii1 in this context is comparable to that obtained in vitro (c.f., Fig. 3A). B, Progress curve of
insulin degradation by CHO-IR cells in the absence or presence of Ii1 (10 mM). Note that insulin catabolism is completely inhibited by Ii1. C–F, Effects
of Ii1 on insulin catabolism in live cells. C, Representative images of live CHO-IR cells pre-loaded with FITC-ins and imaged at various time points in
the presence or absence of Ii1 (10 mM). D,E, Quantitative analysis of intracellular (D) and extracellular (E) FITC fluorescence from 5 replicate
experiments. Data are mean 6 SEM. Note that these experiments were conducted at 22uC. F, Effects of Ii1 on insulin signaling in CHO-IR cells cold-
loaded with insulin. Graph shows IR autophosphorylation (phospho-IR) determined by ELISA in response to 5-min incubation at 37uC in the presence
of Ii1 (10 mM), ML3-XF (10 mM) or vehicle (DMSO). Data are mean 6 SEM of 6 independent experiments, where data are normalized to IR
autophosphorylation obtained for insulin and vehicle alone. *p,0.01. Western analysis of a representative experiment (lower panels) providing
biochemical confirmation of the results obtained by ELISA. G, Preloaded insulin is rapidly catabolized by CHO-IR cells and blocked by IDE inhibitors.
Graph shows amounts of
125I present in CHO-IR cells cold-loaded with
125I-insulin then incubated for 5 min at 37uC in the presence of IDE inhibitors
(10 mM) or vehicle then washed to remove insulin catabolites. Data are mean 6 SEM of 4 experiments expressed as a percentage of
125I present in
control cells maintained at 4uC.
doi:10.1371/journal.pone.0010504.g005
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and selective inhibitors of IDE or, indeed, of any member of the
inverzincin superfamily of zinc-metalloproteases [16]. Given the
longstanding interest in IDE in general, and the predicted
therapeutic value of IDE inhibitors in particular, why has their
development proved so elusive for so long? The answer can be
traced to the distinctive structure of IDE’s active site, which in turn
reflects the separate evolutionary origins of this protease
superfamily [7]. As documented by earlier studies [9,18] and the
present work, IDE’s active site is bipartite, consisting of two
distinct domains contained within the C- and N-terminal halves of
the protease. The active site becomes fully formed only when the
protease is in the closed conformation, and it is disrupted
completely upon transition to the open conformation. These very
large conformational changes occurring during the catalytic cycle
of IDE essentially render its active site a ‘‘moving target,’’ one that
cannot easily be stably occupied by small molecules, even those
containing a strong zinc-binding moiety. As our co-crystal
structure reveals, the potency of Ii1 can be traced to its unique
ability to interact simultaneously with both the N- and C-terminal
portions of the active site. In so doing, Ii1 appears to ‘‘lock’’ the
protease in the closed, inactive conformation—a feature that is
likely to be indispensable for effective IDE inhibitors.
Second, these IDE inhibitors grant several new insights into the
enzymology of this poorly understood protease. A particularly
puzzling property is the substrate-dependence of Ki values for
inhibition of IDE by Ii1, wherein smaller substrates show lower Ki
values than larger substrates. These two categories of substrate
have in fact been shown to exhibit strikingly different behaviors in
multiple contexts. For example, the hydrolysis of short sub-
strates—but not longer ones—can be profoundly activated by
ATP and other nucleotide polyphosphates [30,31], inorganic
triphosphate [30,31], as well as by structurally unrelated drug-like
molecules [23]. In terms of the differences in Ki values, we
speculate that larger substrates may be more capable than smaller
ones of effecting the transition between the closed and open
configurations, resulting in an increased off rate for the inhibitor. It
may also be that the inhibitor can be trapped inside the internal
chamber only in the case of smaller substrates [23]. Alternatively,
given that 2 residues within Ii1 protrude into the internal chamber,
it may be that larger substrates sterically block a subset of binding
modes of the inhibitor. In this context, it is relevant to note that
larger substrates are known to interact with an exosite present
inside the catalytic chamber but opposite to the active site [9]. It is
conceivable that larger substrates utilize this exosite as a point of
leverage for larger substrates that normally helps position the
substrate into the active site, but which may at the same time have
the effect of pushing out an inhibitor. The finding that Hill slopes
were consistently ,1 is also noteworthy. Given that IDE normally
exists as a homodimer [32,33], this may be explained by
intersubunit interactions, wherein the closing of one subunit, for
example, by binding to inhibitor, favors the opening of the other
subunit. Consistent with this idea, Song et al. recently reported [34]
that a homodimerization-deficient IDE mutant exhibits markedly
different enzymological properties than normal homodimeric IDE.
For example, this mutant is not activated by polyphosphates or by
other substrates [34]. Together with our own findings, these results
suggest that intersubunit interactions powerfully influence the
activity and substrate selectivity of IDE, possibly by influencing the
transitions between the closed and open configurations of each
subunit. Yet another interesting enzymological point emerges from
the dose-response studies: the range of doses tested overlapped the
nominal enzyme concentration (1 nM); nevertheless, the sigmoidal
shape of the corresponding dose-response curves implies a much
smaller amount of active enzyme. Consistent with the conclusions
of previous studies [9,31], this result suggests that the vast majority
of the protease is normally in the closed, inactive configuration.
The finding that only a small fraction of IDE molecules are
normally active at any one time may also help to account for IDE’s
ability to be profoundly activated by multiple ligands
[23,30,31,35]. Finally, the observation that Ii1 exhibits a purely
competitive mode of inhibition is notable, because it suggests zinc-
binding may not be the sole determinant of inhibitor potency;
instead, this finding reinforces the idea that the inhibitory power of
Ii1 may be better explained by its ability to stabilize the closed,
inactive conformation, by virtue of joint interactions with both the
N- and C-terminal domains of the protease.
A third significant implication of our study relates to the degree
to which Ii1 is selective for IDE vis-a `-vis other zinc-metallopro-
teases (,4 orders of magnitude), which is especially impressive
given their peptidic nature. While we emphasize that we cannot
exclude the possibility that these compounds cross-react with
other zinc-metalloproteases we did not test, it is significant to note
that IDE was not inhibited at all even by broad-spectrum
hydroxamic acid inhibitors of conventional zinc-metalloproteases
(Table S2). These twin findings strongly suggest that it may be
possible to develop highly selective IDE inhibitors, even inhibitors
containing the potent hydroxamic acid moiety. In this context, it
is notable that hydroxamic acids were once considered to be
attractive candidates for several therapeutic applications and,
indeed, continue to be tested in human trials [36]; however, as a
general class, hydroxamic acid protease inhibitors fell out of favor
due to a series of disappointing clinical results [37], which are
commonly attributed to an innate lack of selectivity of the
hydroxamic acid moiety. The remarkable degree of selectivity
observed for Ii1 supports the alternative interpretation that the
aforementioned clinical failures might instead be attributed to
liabilities inherent in the targets of the tested compounds—more
specifically, to the high degree of structural relatedness and sheer
number of conventional zinc-metalloproteases present in higher
mammals. Given the marked evolutionary and structural
divergence of the inverzincin superfamily, and the low number
of its membership, we speculate that it may be feasible to develop
hydroxamate inhibitors of IDE with far fewer off-target effects.
We emphasize, however, that it should also be possible to develop
effective IDE inhibitors containing alternative zinc-binding
moieties.
Fourth, and perhaps most significantly from a biomedical
perspective, the IDE inhibitors we developed show novel and
potentially medicinally valuable effects on insulin signaling.
Whereas IDE inhibitors have long been predicted to slow the
catabolism of circulating insulin [38], we show here that IDE
inhibitors also potentiate the action of insulin subsequent to its
binding to the IR. Notably, the latter effect occurs on a time scale
that is inconsistent with effects on extracellular insulin catabolism,
but instead appears to be attributable to decreased degradation of
internalized insulin, which is normally rapidly catabolized [29].
Thus, IDE inhibitors with appropriate pharmacokinetic properties
may be useful in combating diabetes by virtue of both ‘‘insulin
sparing’’ and ‘‘insulin sensitizing’’ effects. It is worth noting here
that the wisdom of inhibiting IDE has been called into question by
results from mice genetically deleted for the IDE gene [5]. In
particular, IDE knockout mice have themselves been shown to
develop a diabetic phenotype [5]. However, it is critical to
recognize that this phenotype is a compensatory change that
emerges only as a secondary consequence of chronic hyperinsu-
linemia (S. Abdul-Hay, A. DelleDonne, L. Li, J. Zhao & M.
Leissring, unpublished observations; see also [5]). In contrast to the
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drugs that only partially or transiently block IDE activity and/or
target only a subset of IDE molecules would not be expected to
give rise to these compensatory changes, but would instead be
expected to improve glycemic control [38]. IDE knockout mice
also show elevated levels of cerebral Ab, raising concern that
chronic inhibition of IDE could increase the risk for AD [5].
However, pharmacological inhibitors of IDE could easily be
engineered to be blood-brain barrier impermeant, thereby
obviating this concern. Moreover, in light of the recent finding
that intranasal insulin improves cognition in early AD patients
[39], and given insulin’s beneficial effects on learning and memory
[1], it may be overly simplistic to assume that IDE’s role in AD
pathogenesis is limited to its predicted effects on Ab alone.
Finally, the inhibitors we have developed constitute important
new tools for the experimental manipulation of IDE, tools that
are long overdue [16]. In this connection, it is significant to note
that EDTA does not inhibit IDE except after prolonged
incubation [18,40]. The use of IDE inhibitors might therefore
be critical for many routine experimental as well as clinical
applications involving short peptides. Thus, despite their
peptidic nature, the IDE inhibitors described herein should be
of immediate use for addressing a number of outstanding
questions concerning the chemical biology of this important
p r o t e a s e ,a sw e l la sf o ra c c u r a t e ly quantifying its substrates.
Moreover, the insights derived from our co-crystal structure, the
first IDE-inhibitor complex, provide a key starting point for the
development of more drug-like IDE inhibitors. Given that IDE
resides predominantly in the cytosol and other intracellular
compartments [41], where its function remains ill-defined, the
development of cell-permeant IDE inhibitors will be a
particularly important goal. Furthermore, the development of
IDE inhibitors that are stable and non-toxic in vivo will permit a
more thorough evaluation of the physiological and pathophys-
iological roles of IDE proteolytic activity in animal models of
disease, which in turn could lead to new treatments for diabetes
and other disorders.
Methods
Analysis of IDE’s cleavage-site specificity
To determine the amino acids preferred by IDE at positions C-
terminal to the scissile bond, IDE was allowed to partially
hydrolyze a mixture of N-terminally acetylated 12-mer peptides
(Ac-XXXXXXXXXXXX-amide, where ‘‘X’’ refers to any amino
acid except cysteine). The resulting C-terminal peptide fragments,
containing unblocked N-termini, were analyzed by successive
rounds of Edman degradation as described [22]. To determine
amino acids preferred at positions N-terminal to the scissile bond,
the results of the above analysis were used to generate a second
peptide mixture (MGXXXXYKPEDK [K-biotin]-amide) de-
signed to promote hydrolysis N-terminal to the sequence YKPE.
Following partial hydrolysis with IDE, biotinylated species,
comprising intact peptides and C-terminal fragments, were
removed with an avidin column, and the remaining peptides,
consisting of freshly cleaved N-terminal fragments, were analyzed
by Edman degradation.
Synthesis of conventional peptide hydroxamic acids
The synthesis of the conventional peptide hydroxamic acids is
described in Fig. S8. Synthesis of distereomerically pure
intermediates used to confirm the stereochemical assignments of
the conventional peptide hydroxamic acids is also described in
Figs. S9, S10.
Synthesis of retro-inverso peptide hydroxamic acids
9-fluorenylmethyleneoxy-carbonyl (Fmoc)-based solid-phase
peptide peptide synthesis was carried out manually using a 2-
chlorotritylhydroxyl amine resin (Sigma-Aldrich). Following de-
protection of the resin with 20% piperidine in dichloromethane
(DCM), Fmoc-protected b-D-amino acids (5 eq.) were coupled in a
16-hr reaction using HATU (5 eq.), HOAt (5 eq.) and DIEA (10
eq.) in DCM, and subsequent amino acids (4 eq.) were coupled
using HBTU (4 eq.), HOBt (4 eq.) and DIEA (4 eq.) in
dimethylformamide (DMF). Cleavage from the resin and removal
of protecting groups was effected by a mixture of trifluoroacetic
acid (95%), triisopropylsilane (2.5%) and water (2.5%).Peptides
were purified by reverse-phase liquid chromatography using a
linear acetonitrile:water gradient and masses were verified by
matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry.
Crystallization and structural refinement of IDE-Ii1
complex
IDE-CF-E111Q, a catalytically inactive IDE mutant free of
cysteines (C110L, C171S, C178A, C257V, C414L, C573N,
C590S, C789S, C812A, C819A, C904S, C966N, and C974A)
was constructed using the QuickChange Multi Site-Directed
Mutagenesis Kit according to manufacturer’s recommendations
(Stratagene). IDE-CF has catalytic activity comparable to wild-
type IDE, and IDE-CF-E111Q readily forms diffracting crystals.
Expression and purification of IDE-CF-E111Q were performed as
previously described [42]. The complex of CF-IDE-E111Q and
the peptide hydroxamate Ii1 was formed by mixing protein and Ii1
in a 1:1 molar ratio and isolated by a superdex-200 column.
Crystals of IDE-Ii1 were grown by hanging drop and cryopro-
tected as described [42]. Data from a crystal that diffracted to 2.6
A ˚ resolution was collected at 100 K at the Advanced Photon
Source Structural Biology Center ID19 (Argonne, IL) and
processed with the programs HKL2000/SCALEPACK [43].
Using substrate-free IDE-Y831F (PDB code 2JG4; Ref [31]) as
the model in PHASER [44], a satisfactory molecular replacement
solution of IDE-Ii1 was obtained. Refinement of the model was
performed using anisotropic scaling, bulk solvent correction, rigid
body refinement, coordinate and individual restraint B factor
refinement, and simulated annealing using PHENIX [45].
Building of IDE structure was performed using Coot [46].
Simulated annealing 2Fo–Fc composite omit map was then
calculated using CNS [47] and used in modelling Ii1 at the active
site. The final model of IDE-Ii1 (PDB code 3E4A) had Rwork and
Rfree of 16.7% and 22.5%, respectively. The statistics of diffracting
data and refinement are summarized in Table S3.
In vitro enzymatic assays
IDE activity was quantified by monitoring hydrolysis of FRET1
[31], SP1 [23], FAbB [17] or
125I-insulin [48] as described
previously, using recombinant human IDE purified from bacteria
[33]. Degradation of unmodified recombinant human insulin
(Sigma-Aldrich) and FITC-ins [28] (Invitrogen) was assessed using
a homogeneous time-resolved fluorescence (HTRF)-based assay
(CIS-Bio). Quantitative kinetic data were derived by hyperbolic
regression analysis using the computer program HYPER.EXE
created by John S. Easterby (University of Liverpool). Activity of
cathepsin B was assessed by monitoring hydrolysis of Z-LR-AMC
(Enzo Life Sciences International), that of cathepsin D using the
Cathepsin D Assay Kit (Sigma-Aldrich), and that of the 20S
proteasome using the 20S Proteasome Assay Kit for Drug
Discovery (Enzo Life Sciences International). The activity of all
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of OmniMMP
TM Fluorogenic Substrate (Enzo Life Sciences
International).
Cell-based extracellular insulin degradation assays
Recombinant human insulin (Sigma) was applied to CHO-IR
cells or HeLa cells grown to near-confluency on 96-well plates
under normal cell culture conditions, and its disappearance over
time in the presence of different concentrations of IDE inhibitors
or vehicle was quantified using a HTRF-based insulin assay (CIS-
Bio). CHO-IR cells were a generous gift from Dr. Michel Bernier
(National Instutute on Aging) and HeLa cells were purchased from
American Type Culture Collection.
Live-cell imaging of intracellular insulin catabolism
CHO-IR cells were cultured on poly-D-lysine glass bottom
culture dishes (MatTek Corp.), loaded with FITC-ins [28] (2 mM;
Invitrogen) for 2 h at 37uC, washed with Hank’s balanced salt
solution (HBSS), then imaged consecutively at fixed intervals by
fluorescence microscopy at 22uC. Intracellular and extracellular
fluorescence in the resulting images was quantified using
MetaMorph software according to manufacturer’s recommenda-
tions (Molecular Devices).
IR autophosphorylation assays
CHO-IR cells were grown to near confluency in 6-well plates,
washed, then starved for 6 h in insulin-free medium (DMEM/
0.1% BSA). Cells were then cold-loaded with human insulin
essentially as described [49]. Briefly, after cooling the cells to 4uC,
the medium was replaced with ice-cold HBSS/1% BSA
supplemented with insulin (10 nM), incubated at 4uC for 1 h,
washed 3 times with ice-cold HBSS/1% BSA. After addition of
ice-cold HBSS/1% BSA supplemented with IDE inhibitors
(10 mM) or DMSO, the cells were incubated at 37uC for 5 min,
then rapidly cooled on ice. Cell lysates were harvested using
manufacturer-provided cell-lysis buffer (Cell Signaling Technolo-
gy) supplemented with additional phosphatase inhibitors (Milli-
pore). IR autophosphorylation (Tyr 1146) and total IR levels were
quantified by ELISAs (Cell Signaling Technology), and confirmed
by western blotting with the same antibodies used for ELISAs or
GAPDH as a loading control.
Quantification of prebound insulin catabolism
Confluent monolayers of CHO-IR cells grown in 6-well culture
dishes were cold loaded with 240 pM
125I-insulin for 1 h and
washed 3 times with ice-cold HBSS/1% BSA. Following addition
of ice-cold HBSS/1% BSA supplemented with IDE inhibitors
(10 mM) or DMSO, the cells were incubated at 37uC for 5 min (or
as a control, maintained at 4uC), then rapidly cooled on ice and
washed two times with ice-cold HBSS/1% BSA supplemented
with Complete protease inhibitor cocktail (Roche) and Ii1
(10 mM). Following harvesting of cells by scraping,
125I levels
were quantified by gamma counter (Beckman).
Supporting Information
Table S1 Examples of known IDE inhibitors.
Found at: doi:10.1371/journal.pone.0010504.s001 (0.03 MB
DOC)
Table S2 IDE inhibition by commercially available
hydroxamic acids.
Found at: doi:10.1371/journal.pone.0010504.s002 (0.05 MB
DOC)
Table S3 Crystallographic statistics.
Found at: doi:10.1371/journal.pone.0010504.s003 (0.07 MB
DOC)
Table S4 Potency of derivatized retro-inverso peptide
hydroxamates.
Found at: doi:10.1371/journal.pone.0010504.s004 (0.03 MB
DOC)
Figure S1 IDE inhibitors identified through high-
throughput screening of ,115,000 compounds. A, Exam-
ples of thiol-alkylating compounds, which made up the majority of
identified inhibitors. B, Compound showing modest inhibition of
IDE whose potency was not improved despite extensive medicinal
chemistry efforts. C, Nullscript, a small-molecule hydroxamic acid,
was the only inhibitor apart from thiol-alkylating compounds to
show submicromolar potency.
Found at: doi:10.1371/journal.pone.0010504.s005 (0.06 MB
TIF)
Figure S2 Structural comparison of conventional (A)
and retro-inverso (B) peptide hydroxamates. Note that, in
the retro-inverso compounds, the a-carbon adjacent to the
hydroxamic acid moiety requires the use of b-amino acids, and
that D-isomers must be used at all positions to mimic the relative
orientation of residues in conventional peptides.
Found at: doi:10.1371/journal.pone.0010504.s006 (0.06 MB
TIF)
Figure S3 Kinetic of Ii1-mediated inhibition of Ab
degradation. A, Lineweaver-Burk plot of IDE-mediated Ab
degradation in the absence or presence of Ii1 (30 nM). B,
Quantitative kinetic data derived from A. Note pure competitive
mode of inhibition. n=4 replications.
Found at: doi:10.1371/journal.pone.0010504.s007 (0.10 MB
TIF)
Figure S4 Surface representation of IDE showing the
interior of the catalytic chamber defined by the N- and
C-terminal domains. IDE-N and IDE-C are rotated by 290
degree (left) and +90 degree (right) with respect to IDE represented
in the ribbon diagram above. Surfaces are colored by electrostatic
potentials less than 6kT (red) or greater than +6kT (blue). The
catalytic chamber of IDE-Ii1 contained extra electron density in
the region previously shown to accommodate the N-terminus of
substrates, which interact with the exosite of IDE. This extra
electron density was fitted by a tri-alanine peptide. Surface
potentials are displayed with Pymol. The monomeric IDE in the
ribbon diagram is colored as green, blue, yellow and red for domains
1, 2, 3 and 4, respectively. The molecular surface of IDE is color
coded by electrostatic potential, as calculated by APBS2. Ii1 and
tri-alanine peptide are drawn in stick representation. Carbon,
nitrogen, and oxygen atoms of Ii1 and the main chains of peptide
at the exosite are colored orange, blue, and red, respectively. Figure
generated using Pymol.
Found at: doi:10.1371/journal.pone.0010504.s008 (1.58 MB
TIF)
Figure S5 Effects of Ii1 on catabolism of extracellular
insulin in HeLa cells.- A, Dose-response curve of Ii1-mediated
inhibition of insulin degradation by HeLa cells. Note that the
potency of Ii1 in this context is comparable to that obtained in vitro
(c.f., Fig. 3A). B, Progress curve of insulin degradation by HeLa
cells in the absence or presence of Ii1 (10 mM). Note that insulin
catabolism is completely inhibited by Ii1.
Found at: doi:10.1371/journal.pone.0010504.s009 (0.05 MB
TIF)
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based assays. A, B, Potential cytotoxicity of Ii1 and ML3-XF
evaluated by lactose-dehydrogenase release (A) and (3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) (B) conversion assays. Assays were conducted on
confluent CHO-IR cells using the CytoTox 96
TM and the CellTiter
96H AQueous Non-Radioactive Cell Proliferation Assay (ProMega)
according to manufacturer’s recommendations. Essentially identical
results were obtained with HeLa cells (not shown).
Found at: doi:10.1371/journal.pone.0010504.s010 (0.12 MB
TIF)
Figure S7 Confirmation that FITC-labeled species se-
creted by FITC-insulin-loaded CHO-IR cells are pre-
dominantly breakdown products. A, Relative fluorescence
intensity of conditioned medium (CM) from FITC-insulin-loaded
cells, unconditioned medium, CM from unloaded cells, and-as a
key control-the latter medium supplemented with intact FITC-
insulin such that the fluorescence is equivalent to that in the CM
from FITC-insulin-loaded cells. B, Levels of intact insulin present
in the latter samples quantified using a homogeneous time-
resolved fluorescence-based assay (CIS-Bio). Note that levels of
intact insulin are greatly reduced in the CM from FITC-insulin-
loaded cells as compared to that in CM from unloaded cells
supplemented with a fluorescent equivalent of intact insulin. C,
Surface-enhanced laser desorption/ionization-time of flight
(SELDI-TOF) spectra from CM supplemented with intact
FITC-insulin (upper panel) or CM from FITC-insulin-loaded cells
(lower panel). Note that intact FITC-insulin (expected
mass=6197.4; observed mass 6196.37) is detectable in the former
sample, but only fragments thereof are detected in the latter.
Found at: doi:10.1371/journal.pone.0010504.s011 (0.35 MB
TIF)
Figure S8 Synthetic scheme for inhibitor Ii1. a) 10% Pd/C,
H2 (1 atm), aqueous NaOH, EtOH, rt, 48 h; b) BnBr, K2CO3,
acetone, reflux, 16 h; c) LDA, THF, 278uC, 1 h then
BrCH2CO2t-Bu; d) TFA - CH2Cl2 (1:1), rt, 1 h; e)
t-BuONH2?HCl, DMF, HBTU, DIPEA; f) 10% Pd/C, H2 (1
atm), EtOH; g) EtO(C=O)Cl, Et3N, THF/DMF, 220uC, 30 min
then NH2-Arg(Pbf)-allyl?HCl, Et3N, 220uC for 1 h then rt for
16 h; h) chromatography on silica gel; i) Pd(PPh3)4, morpholine; j)
HBTU, DIPEA; k) 10% Pd/C, H2 (1 atm), EtOH/MeOH; l) 5%
anisole in TFA, 40uC, 4.5 h; m) reverse HPLC purification.
Hydrocinnamic acid, 2a, was purchased from Sigma-Aldrich.
2-naphthalenepropanoic acid (2b): A mixture of 3-(2-
naphthyl)acrylic acid (1, 1 g, 0.54 mmol) and 10% Pd-C
(100 mg) in ethanol (20 mL) was treated with 20% aqueous
NaOH (5 mL) and stirred under hydrogen (1 atm) for 48 h. The
mixture was filtered and the filtrate was acidified with 1N HCl and
the extracted with EtOAc (250 mL). The organic extract was dried
over anhydrous magnesium sulfate, filtered and concentrated to
afford 2b (710 mg, 70%), which was used for the next step without
further purification:
1H NMR (500 MHz, DMSO-d6): d 2.64 (t,
2H, J=7.8), 2.99 (t, 2H, J=7.8), 7.41–7.49 (m, 3H), 7.72 (s, 1H),
7.82–7.87 (m, 3H), 12.16 (br s, 1H). Procedure for the Preparation
of Esters 3a and 3b A mixture of the acid (2a, 1.5 g, 10 mmole)
and potassium carbonate (1.4 g, 10 mmole) in acetone ( 30 ml)
was treated with benzyl bromide (1.3 ml, 11 mmole) while stirring
at room temperature and heated at reflux overnight. The reaction
mixture was cooled, filtered and evaporated to an oil. The
resultant oil was purified by silica gel column chromatography
with 5% EtOAc in hexane to give 3a as a colorless oil (1.92 g,
80%):
1H NMR (500 MHz, CDCl3): d 2.69 (t, 2H, J=8.0), 2.97 (t,
2H, J=7.8), 5.11(s, 2H), 7.18–7.21 (m, 3H), 7.26–7.37 (m, 7H).
3b (oil, 1.26 g, 87%):
1H NMR (500 MHz, CDCl3): d 2.79 (t, 2H,
J=7.5), 3.15 (t, 2H, J=7.8), 5.12 (s, 2H), 7.27–7.34 (m, 6H),
7.41–7.48 (m, 2H), 7.63 (s, 1H), 7.75–7.82 (m, 3H). Procedure for
the Alkylation of Esters 3a and 3b To a stirred solution of LDA
(2.0 M in THF, 2.7 ml, 5.4 mmole) and anhydrous THF (5 ml) at
278uC was dropwise added ester 3a (1.28 g, 5.3 mmole) in THF
(6 ml). After 1 h at 278uC, tert-butyl bromoacetate (0.87 ml,
5.9 mmole) was added neat and the reaction mixture was slowly
allowed to warm to room temperature overnight. A saturated
aqueous ammonium chloride solution (2 ml) was added to the
reaction mixture followed by EtOAc (100 ml). The organic layer
was washed with saturated sodium chloride (100 ml), dried over
anhydrous sodium sulfate, filtered, evaporated to give an oil. The
resultant oil was purified by silica gel column chromatography
with 7% EtOAc in hexane to give crude 4a (1.2 g, 63% mixture of
mono- and dialkylated ester) as a colorless oil and used for the next
step without further purification. 4b (oil, 830 mg, 40%):
1H NMR
(500 MHz, CDCl3): d 1.38 (s, 9H), 2.39 (dd, 1H, J=5.0, 16.5),
2.65 (dd, 1H, J=8.8, 17.3), 2.94 (dd, 1H, J=7.5, 13.0), 3.17–3.26
(m, 2H), 5.05 (d, 1H, J=12.0), 5.11 (d, 1H, J=12.5), 7.16–7.19
(m, 2H), 7.22–7.29 (m, 4H), 7.42–7.48 (m, 2H), 7.58 (s, 1H), 7.73–
7.76 (m, 2H), 7.78–7.81 (m, 1H). Procedure for the Deprotection
of Alkylated Esters 4a and 4b to acids 5a and 5b A mixture of the
ester (4a, 1.2 g, 3.78 mmole, crude mixture (see above)) and TFA
(10 ml) in dichloromethane (20 ml) was stirred at room temper-
ature for 4 h. The reaction mixture was evaporated to give an oil,
which was purified by silica gel column chromatography with 30%
EtOAc in hexane to give 5a as a colorless oil, which solidified
under house vacuum (530 mg, 53% from crude starting
material):
1H NMR (500 MHz, CDCl3): d 2.47 (dd, 1H, J=4.5,
17.5), 2.75 (dd, 1H, J=9.5, 17.0), 2.79 (dd, 1H, J=8.5, 13.5), 3.08
(dd, 1H, J=6.3, 13.8), 3.15–3.20 (m, 1H), 5.11 (s, 2H), 7.12–7.13
(m, 2H), 7.19–7.35 (m, 8H). 5b (waxy oil, 770 mg, 95%):
1H NMR
(500 MHz, CDCl3): d 2.50 (dd, 1H, J=4.8, 17.3), 2.78 (dd, 1H,
J=9.0, 17.5), 2.96 (dd, 1H, J=7.5, 13.0), 3.21–3.30 (m, 2H), 5.09
(dd, 2H, J=12.3, 15.3), 7.17–7.19 (m, 2H), 7.22–7.28 (m, 4H),
7.42–7.48 (m, 2H), 7.58 (s, 1H), 7.73–7.76 (m, 2H), 7.78–7.81 (m,
1H). Procedure for the Preparation of Protected Hydroxamates 6a
and 6b A mixture of the acid (5a, 600 mg, 2 mmole) and HBTU
(770 mg, 2.02 mmole) in anhydrous DMF (20 ml) was stirred at
room temperature for 1 h. Then O-tert-butylhydroxylamine HCl
(265 mg, 2.1 mmole) and DIPEA (0.74 ml, 2.1 mmole) were
added and the resulting reaction mixture was stirred overnight.
The reaction mixture was diluted with EtOAc (100 ml), washed
with saturated sodium chloride (100 ml), dried over anhydrous
sodium sulfate, filtered, evaporated to give an oil. The resultant oil
was purified by silica gel column chromatography with 20%
EtOAc in hexane to give 6a (oil, 700 mg, 95%):
1H NMR
(500 MHz, DMSO-d6): d 1.11 (s, 9H), 2.20 (dd, 1H, J=5.5, 15.0),
2.36 (dd, 1H, J=9.0, 15.5), 2.79–2.80 (m, 2H), 3.07–3.13 (m, 1H),
4.99 (s, 2H), 7.11–7.12 (m, 2H), 7.20–7.35 (m, 8H), 10.36 (s, 1H).
6b (oil, partially purified, mixture of product and acid-starting
material). Procedure for the Preparation of Acids 7a and 7b A
mixture of hydroxamate (6a, 700 mg, 1.89 mmol) and 10% Pd-C
(200 mg) in ethanol (20 mL) was stirred under hydrogen (1 atm)
for 16 h. The mixture was filtered and concentrated to afford 7a
(white solid, 480 mg, 90%), which was used for the next step
without further purification:
1H NMR (500 MHz, DMSO-d6): d
1.12 (s, 9H), 2.06 (dd, 1H, J=5.8, 15.0), 2.28 (dd, 1H, J=8.8,
15.3), 2.73 (dd, 1H, J=6.8, 13.3), 2.86 (dd, 1H, J=7.3, 13.3),
2.93–2.98 (m, 1H), 7.16–7.22 (m, 2H), 7.27–7.30 (m, 3H), 10.31 (s,
1H), 12.24 (br s, 1H). 7b (purified by silica gel column
chromatography with 5% MeOH in DCM, white foam,
220 mg, 80%):
1H NMR (500 MHz, DMSO-d6): d 1.12 (s, 9H),
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1H, J=6.3, 12.8), 3.02–3.08 (m, 2H), 7.35–7.40 (m, 1H), 7.45–
7.51 (m, 2H), 7.68 (s, 1H), 7.83–7.89 (m, 3H), 10.32 (s, 1H), 12.30
(br s, 1H). Procedure for the Preparation of Amides 8a–10b Acid
7a (140 mg, 0.5 mmole) was dissolved in anhydrous THF (5 ml)
and anhydrous DMF (1 ml) and cooled to 220uC. A solution of
triethylamine (0.075 ml, 0.54 mmole) in THF (1 ml) was added
dropwise to acid 7a, followed by a solution of ethyl chloroformate
(0.048 ml, 0.5 mmole) in THF (1 ml). The reaction mixture was
stirred at 220uC for 1h and the treated with NH2-Arg(Pbf)-
Allyl?HCl ( 380 mg, 0.55 mmole) and triethylamine (0.093 ml,
0.67 mmole) and stirred 1h at 220uC before slowly warmed to
room temperature overnight. The reaction mixture was diluted
with EtOAc (150 ml), washed sequentially with 0.5N HCl
(100 ml), saturated sodium bicarbonate (100 ml), saturated sodium
chloride (100 ml) and then dried over anhydrous sodium sulfate,
filtered, evaporated to give a white foam. The resultant foam was
purified by silica gel column chromatography with 5% MeOH in
DCM to give 8a (foam, 270 mg, 74%). The diastereomers 8a was
separated by silica gel column chromatography with 3% MeOH in
DCM to give 9a (foam, (R)-form, 125 mg, 34%) as first eluting
peak:
1H NMR (500 MHz, CDCl3): d 1.18 (s, 9H), 1.40–1.80 (m,
4H), 1.46 (s, 6H), 1.66–1.72 (m, 1H), 1.85–1.91 (m, 1H), 2.09 (s,
3H), 2.21–2.24 (m, 1H), 2.52 (s, 3H), 2.53–2.60 (m, 1H, overlap
with s), 2.58 (s, 3H), 2.67 (m, 1H), 2.95 (s, 2H), 2.95–2.97 (m, 1H),
3.16 (broad, 2H), 4.45–4.61 (m, 3H), 5.25–5.33 (m, 2H), 5.82–
5.92 (m, 1H), 6.35 (broad d, 1H, J=7.5), 6.44 (broad s, 1H), 7.15–
7.16 (m, 2H), 7.20–7.23 (m, 1H), 7.26–7.30 (m, 2H), 8.12 (broad s,
1H), while 10a as second eluting peak (foam, (S)-form, 145 mg,
40%) peak:
1H NMR (500 MHz, CDCl3): d 1.21 (s, 9H), 1.30–
1.38 (m, 2H), 1.45 (s, 6H), 1.54–1.62 (m, 2H), 1.70–1.78 (m, 1H),
2.09 (s, 3H), 2.35–2.38 (m, 1H), 2.44–2.50 (m, 1H), 2.52–2.58 (m,
1H), 2.53 (s, 3H), 2.58 (s, 3H), 2.78–2.83 (m, 1H), 2.95 (s, 2H),
2.96–2.98 (m, 1H, overlap with s), 3.08 (broad, 1H), 3.15–3.21 (m,
1H), 4.31 (broad, 1H), 4.56–4.62 (m, 2H), 5.23–5.31 (m, 2H),
5.83–5.91 (m, 1H), 6.10 (broad, 1H), 6.34 (broad, 1H), 6.75
(broad, 1H), 7.17–7.20 (m, 3H), 7.24–7.25 (m, 2H), 8.40 (broad s,
1H), The diastereomers 8b was also separated by silica gel column
chromatography with 2.5% MeOH in DCM to give 9b (foam,
(R)-form, 120 mg, 40%) as first eluting peak, peak:
1H NMR
(500 MHz, CDCl3): d 1.16 (s, 9H), 1.36–1.66 (m, 4H), 1.45 (s, 6H),
1.85 (broad, 1H), 2.08 (s, 3H), 2.23–2.26 (m, 1H), 2.51 (s, 3H),
2.58 (s, 3H), 2.60–2.66 (m, 1H), 2.84–2.88 (m, 1H), 2.93 (s, 2H),
3.10–3.62 (broad m, 4H), 4.34–4.42 (m, 2H), 4.51–4.55 (m, 1H),
5.17–5.24 (m, 2H), 5.69–5.77 (m, 1H), 5.98 (broad, 1H), 6.43
(broad s, 1H), 6.49 (broad d, 1H, J=8.0), 7.29–7.31 (m, 1H),
7.42–7.47 (m, 2H), 7.58 (s, 1H), 7.73–7.80 (m, 2H), 8.36 (broad s,
1H), while 10b as second eluting peak (foam, (S)-form, 160 mg,
52%) peak:
1H NMR (500 MHz, CDCl3): d 1.07 (broad, 2H), 1.20
(s, 9H), 1.43–1.44 (m, 6H), 1.47–1.70 (broad m, 3H), 2.09 (s, 2H),
2.42–2.47 (m, 1H), 2.52–2.58 (m, 1H), 2.52 (s, 3H), 2.58 (s, 3H),
2.88–2.98 (m, 3H, overlap with s), 2.93 (s, 2H), 3.07–3.12 (m, 1H),
3.19–3.23 (m, 1H), 4.26 (broad, 1H), 4.53 (broad d, 2H, J=6.0),
5.20–5.28 (m, 2H), 5.79–5.85 (m, 1H), 6.26 (broad, 1H), 6.90
(broad, 1H), 7.32–7.34 (m, 1H), 7.37–7.43 (m, 2H), 7.61 (s, 1H),
7.70–7.76 (m, 3H), 8.60 (broad, 1H). Procedure for the
Deprotection of Allyl Esters 9a–10b to acids 11a–12b A solution
of the allyl ester 9a (125 mg, 0.17 mmole) in anhydrous THF
(20 ml) was treated with tetrakis(triphenylphosphine)palladium(0)
(20 mg, 0.017 mmole) and morpholine ( 0.2 ml, 2.29 mmole) at
room temperature for 4 h. The reaction mixture was diluted with
EtOAc (100 ml), washed with 0.5N HCl (100 ml), saturated
sodium chloride (100 ml), dried over anhydrous sodium sulfate,
filtered, evaporated to give a waxy solid. The resultant solid was
purified by silica gel column chromatography with 5% MeOH in
DCM to give 11a (waxy solid, 60 mg, 51%) and used without
further purification. Other Acids 11b–12b were prepared in the
same manner with similar yields and used in the next step without
further purification. Procedure for the Preparation of Protected
Amide 14 The protected dipeptide 14 was obtained as a white
foam (1.16 g, 93%) starting from acid 13 and the HCl salt of NH2-
Glu(tBu)-CONH2 following the general procedure described for
6a and 6b:
1H NMR (500 MHz, DMSO-d6): d 1.39 (s, 9H), 1.61
(s, 9H), 1.70–1.78 (m, 1H), 1.87–1.93 (m, 1H), 2.12–2.22 (m, 2H),
2.90 (dd, 1H, J=10.5, 15.0), 3.09 (dd, 1H, J=3.5, 15.0), 4.18–
4.23 (m, 1H), 4.36–4.40 (m, 1H), 4.92–4.98 (m, 2H), 7.10 (s, 1H),
7.22–7.33 (m, 8H), 7.56 (s, 1H), 7.60 (d, 1H, J=8.0), 7.74 (d, 1H,
J=8.0), 8.03 (d, 1H, J=8.0), 8.09 (d, 1H, J=8.0). Procedure for
the Deprotection of Amide 14 to 15 The deprotected dipeptide 15
was obtained as a white foam (230 mg, 90%) starting from
protected amide 14 following the general procedure described for
7a and 7b:
1H NMR (500 MHz, CDCl3): d 1.45 (s, 9H), 1.68 (s,
9H), 1.88 (sextet, 1H, J=7.5), 2.06–2.12 (m, 1H), 2.22 (dt, 1H,
J=6.8, 17.0), 2.38 (dt, 1H, J=16.5, 7.5), 2.86–2.90 (m, 1H), 3.33
(dd, 1H, J=3.5, 15.0), 3.75 (dd, 1H, J=4.3, 9.3), 4.39–4.43 (m,
1H), 5.41 (br s, 1H), 6.47 (br s, 1H), 7.23–7.26 (m, 1H), 7.30–7.34
(m, 1H), 7.48 (s, 1H), 7.61 (d, 1H, J=8.0), 7.95 (d, 1H, J=8.0),
8.12 (br s, 1H). Procedure for the Preparation of Protected
Tetrapeptide 16a, 16b, 17a and 17b The protected tetrapeptide
16a was obtained as a white foam (138 mg, 70%) starting from
(R)-acid 11a and amine 15 following the general procedure
described for 6a and 6b. See
1H NMRs below. Procedure for the
Preparation of Deprotected Tetrapeptide 18a, 18b, 19a and 19b
A solution of the protected tetrapeptide 16a (100 mg,
0.086 mmole) in TFA (6 ml) was treated with anisole (0.3 mg,
2.76 mmole) and stirred at 40uC for 4.5 h. The reaction mixture
was cooled and the volatiles were removed in vacuo. The resultant
oil was washed with ether (10 ml), dissolved in water (5 ml) and
filtered. The filtrates were lyophilized to give white powders that
were further purified by reverse-phase liquid chromatography
using a linear acetonitrile:water gradient to give 18a as a white
powder:
1H NMR (500 MHz, DMSO-d6): d 1.42–1.53 (m, 3H),
1.65–1.77 (m, 2H), 1.86–1.93 (m, 2H), 2.16–2.20 (m, 2H), 2.26
(dd, 1H, J=9.8, 15.3), 2.45–2.47 (m, 1H, overlap with DMSO),
2.80 (dd, 1H, J=6.0, 13.5), 2.96–3.06 (m, 4H), 3.14 (dd, 1H,
J=4.8, 14.3), 4.16–4.24 (m, 2H), 4.50–4.54 (m, 1H), 6.76 (broad,
1H), 6.96 (t, 1H, J=7.5), 7.04 (t, 1H, J=7.8), 7.09–7.24 (m, 8H),
7.29 (d, 1H, J=7.5), 7.32–7.34 (m, 2H), 7.56 (d, 1H, J=8.5), 7.97
(d, 2H, J=7.5), 8.09 (d, 1H, J=7.5), 8.76 (s, 1H), 10.45 (s, 1H),
10.81 (d, 1H, J=2.0), 12.11 (broad s, 1H); MALDI-MS obsd
694.3308, calcd 694.3235 [(M + H)
+ ,M=C 33H43N9O8]. 18b:
1H NMR (400 MHz, DMSO-d6): d 1.44–1.56 (m, 3H), 1.68–1.79
(m, 2H), 1.87–1.95 (m, 2H), 2.16–2.23 (m, 2H), 2.28–2.31 (m, 1H,
overlap with DMSO), 2.45–2.55 (m, 1H, overlap with DMSO),
2.61–2.64 (m, 1H), 2.94–3.16 (m, 5H), 4.15–4.30 (m, 2H), 4.51–
4.59 (m, 1H), 6.80 (broad, 1H), 6.96 (t, 1H, J=7.2), 7.03 (t, 1H,
J=6.8), 7.09 (s, 1H), 7.14–7.18 (m, 2H), 7.27–7.36 (m, 3H), 7.41–
7.47 (m, 2H), 7.56 (d, 1H, J=8.0), 7.65 (s, 1H), 7.74 (d, 1H,
J=8.8), 7.80–7.82 (m, 2H), 7.95–8.00 (m, 2H), 8.19 (d, 1H,
J=7.6), 8.75 (s, 1H), 10.45 (s, 1H), 10.82 (s, 1H); MALDI-MS
obsd 744.3103, calcd 744.3391 [(M + H)
+ ,M=C 39H45N9O8].
19a:
1H NMR (500 MHz, DMSO-d6): d 1.06–1.09 (m, 2H), 1.14–
1.23 (m,1H), 1.46–1.54 (m, 1H), 1.80–1.88 (m, 1H), 1.98–2.05 (m,
1H), 2.14 (dd, 1H, J=4.0, 14.5), 2.22–2.31 (m, 2H), 2.41 (dd, 1H,
J=10.5, 15.5), 2.61 (dd, 1H, J=6.5, 13.0), 2.71 (dd, 1H, J=9.0,
13.5), 2.84 (q, 2H, J=7.5), 2.93–2.99 (m, 1H), 3.16–3.24 (m, 2H),
3.76–3.80 (m, 1H), 4.09–4.13 (m, 1H), 4.37–4.41 (m, 1H), 6.78
(broad, 1H), 6.86 (s, 1H), 6.97 (t, 1H, J=7.3), 7.05 (t, 1H, J=7.8),
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1H, J=8.0), 7.77 (d, 2H, J=7.5), 8.25 (d, 1H, J=7.0), 8.34 (d,
1H, J=7.0), 8.95 (s, 1H), 10.70 (s, 1H), 10.77 (d, 1H, J=2.5),
12.13 (broad s, 1H), MALDI-MS obsd 694.3321, calcd 694.3235
[(M + H)
+ ,M=C 33H43N9O8].19b:
1H NMR (400 MHz,
DMSO-d6): d 1.47–1.49 (m, 2H), 1.82–1.91 (m, 1H), 2.01–2.05
(m, 1H), 2.13–2.18 (m, 2H), 2.21–2.30 (m, 2H), 2.42–2.54 (m, 2H,
overlap with DMSO), 2.69–2.80 (m, 3H), 2.89–2.94 (m, 1H),
3.04–3.07 (m, 2H), 3.16–3.20 (m, 2H), 3.79–3.84 (m, 1H), 4.09–
4.15 (m, 1H), 4.38–4.42 (m, 1H), 6.70 (broad, 1H), 6.88 (s, 1H),
6.97 (t, 1H, J=7.6), 7.05 (t, 1H, J=7.2), 7.14–7.19 (m, 2H), 7.30–
7.36 (m, 3H), 7.43–7.49 (m, 2H), 7.55 (d, 1H, J=7.6), 7.65 (s, 1H),
7.77 (d, 1H, J=7.6), 7.81–7.86 (m, 3H), 8.25 (d, 1H, J=7.6),
8.39 (d, 1H, J=6.4), 8.95 (s, 1H), 10.70 (s, 1H), 10.78 (s, 1H);
MALDI-MS obsd 744.2910, calcd 744.3391 [(M + H)
+ ,M=
C37H45N9O8].
Found at: doi:10.1371/journal.pone.0010504.s012 (164 KB TIF)
Figure S9 Synthetic scheme for generation of diaster-
eomerically pure conventional peptide hydroxamic
acids. a) t-BuONH2A ˆ?HCl, HBTU, DIPEA; b) LiOH then
HCl. Note that these experiments were conducted to confirm the
stereochemistry assignments made for each diastereomer 18a,
18b, 19a, and 19b (see Fig. S8).
Found at: doi:10.1371/journal.pone.0010504.s013 (0.05 MB TIF)
Figure S10 Alternate synthetic scheme for generation of
conventional peptide hydroxamic acids. a) t-BuONH2?HCl,
HBTU, DIPEA; b) LiOH then HCl; c) EtO2CCl, Et3N, 278uC
then NH2-Arg(Pbf)-allyl?HCl. General Procedure for the Prepara-
tion of Protected Hydroxamates 21 and 23 The protected
hydroxamate 21 obtained as a colorless oil (290 mg, 88%) starting
from (R)-acid 20 following the general procedure described for 6a
and 6b. Also 23 was obtained as a colorless oil (485 mg, 94%)
starting from (S)-acid 22. 21:
1H NMR (500 MHz, CDCl3): d 1.23
(s, 9H), 2.21–2.51 (m, 1H), 2.37–2.80 (m, 1H), 2.83–2.87 (m, 1H),
3.00–3.04 (m, 1H), 3.25 (broad, 1H), 3.65 (s, 3H), 7.14–7.15 (m,
2H), 7.20–7.23 (m, 1H), 7.27–7.30 (m, 2H), 7.75–7.90 (broad m,
1H). 23:
1H NMR (500 MHz, CDCl3): d 1.19–1.22 (m, 9H), 2.21–
2.84 (m, 1H), 2.40–2.84 (m, 1H), 2.99–3.04 (m, 1H), 3.18–3.24 (m,
1H), 3.34 (broad, 1H), 3.66 (s, 3H), 7.28–7.30 (m, 1H), 7.43–7.48
(m, 2H), 7.60 (broad s, 1H), 7.67 (broad, 1H), 7.77–7.82 (m, 3H).
General Procedure for the Hydrolysis of Methyl Esters 21 and 23
to acids (R)-7a and (S)-7b A solution of the methyl ester 21
(335 mg, 1.14 mmole) in methanol (20 ml) and water (3 ml) was
treated with LiOH monohydrate (96 mg, 2.28 mmole) in water
(5 ml) at OuC for 6 h. The reaction mixture was diluted with water
(10 ml), acidified with 1N HCl (to pH 2) and extracted with DCM
(50 ml63). The organic layer was washed saturated sodium
chloride (100 ml), dried over anhydrous sodium sulfate, filtered,
and evaporated to give a waxy solid. The resultant solid was
purified by silica gel column chromatography with 2% MeOH in
DCM to give (R)-7a (waxy solid, 170 mg, 53%) and used without
further purification. Acid (S)-7b was in prepared in a similar
manner and a similar yield and used without further purification.
Procedure for the Synthesis of 10b The protected dipeptide 10b
was obtained as a white foam (80 mg, 73%) starting from (S)-acid
7b and Pbf-protected arginine allyl ester HCl salt following the
general procedure described for 6a and 6b. The TLC profile and
1H NMR were the same for this material as those prepared by the
separation of diastereomers. Procedure for the Synthesis of 18a
The protected dipeptide 9a was obtained as a white foam (130 mg,
29%) starting from (R)-acid 7a and Pbf-protected arginine allyl
ester HCl salt following the general procedure described for 6a
and 6b. The TLC profile and
1H NMR were the same for this
material as those prepared by the separation of diastereomers. The
deprotected 18a was obtained from 9a as described above. In
addition, this material demonstrated the same in vitro activity as the
material prepared by the separation of diastereomers.
Found at: doi:10.1371/journal.pone.0010504.s014 (0.07 MB
TIF)
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